Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats
Frontiers in Pharmacology · 12.08.2026 · 17
DOI: 10.3389/fphar.2026.1875749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.08.2026. Verfasst von Xiaohuan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Operating Room, Changzhou Cancer Hospital, Changzhou, China. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Montmorillonite powder (MP) can adsorb pyrotinib and reduce its bioavailability. This study investigated the effects of different dosing intervals on the pharmacokinetic interaction between MP and pyrotinib in rats.
Methods
Eighteen male Sprague-Dawley rats were randomly assigned to three groups (n = 6/group): Control (pyrotinib alone), 0.5-h interval (MP given 0.5 h after pyrotinib), and 2.0-h interval (MP given 2.0 h after pyrotinib). Pyrotinib (10 mg/kg) was orally administered to all rats, followed by MP (240 mg/kg) or water (control) at designated time points. Blood samples were collected up to 24 h post-dose. Plasma pyrotinib concentrations were determined by a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated using WinNonlin.
Results
The 0.5-h interval group showed substantially reduced pyrotinib exposure, with area under the curve (AUC) from time zero to last time point (AUC last ) and AUC from time zero to infinity (AUC inf ) decreasing by 31.2% and 31.3%, respectively, indicating statistically significant reductions (90% CIs <1.0). C max reduction was 20.7%, which was not statistically significant (90% CI crossed 1.0). For the 2.0-h interval group, all GMRs were close to unity, but the wide 90% CIs (69.1%–137.6%) could not rule out a clinically meaningful impact.
Conclusion
In rats, MP administration at an insufficient dosing interval markedly compromises pyrotinib systemic exposure, whereas adequate temporal separation largely mitigates this interaction. These findings underscore the urgent need for dedicated clinical pharmacokinetic studies to define the optimal dosing interval in humans and to minimize the risk of subtherapeutic pyrotinib exposure in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Operating Room, Changzhou Cancer Hospital, Changzhou, China.
- Office of Clinical Trial Institution, Changzhou Cancer Hospital, Changzhou, China.
- Department of Medical Oncology, Changzhou Cancer Hospital, Changzhou, China.
- Department of Pharmacy, Changzhou Cancer Hospital, Changzhou, China.
- Department of Radiotherapy, Changzhou Cancer Hospital, Changzhou, China.
Zitieren
APA
Gao, X., He, G., Bi, Y., Luo, H., Wu, J., Zu, Y., Ji, Y., & Yu, J. (2026). Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1875749
Vancouver
Gao X, He G, Bi Y, Luo H, Wu J, Zu Y, et al. Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1875749
BibTeX
@article{Gao2026,
author = {Gao, Xiaohuan and He, Guangzhao and Bi, Yanzhi and Luo, Hui and Wu, Jing and Zu, Yuanyuan and Ji, Yun and Yu, Jingping},
title = {Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1875749}
}
EUVIMED